Menopause · Bleeding

Vaginal spotting after menopause: why it happens and when to worry.

Even a single pink spot on toilet paper after menopause deserves a call to your clinician. Most causes are benign — but ruling out the ~10% that are not is what makes early evaluation life-saving.

The short answer

Vaginal spotting after menopause is technically postmenopausal bleeding — bleeding after 12 consecutive months without a period. About 90% of cases are benign (atrophy, polyps, HRT), but ~9–10% represent endometrial cancer, which is highly curable when found early. That single fact is why every episode needs evaluation.

The most common causes

Vaginal / endometrial atrophy: ~60–70% of cases. Fragile tissue bleeds after friction (intercourse, exercise, wiping).
Endometrial or cervical polyps: ~10–15%. Benign overgrowths that bleed intermittently.
Hormone therapy: ~5–10%. Expected on sequential regimens; unpredictable for the first 3–6 months on continuous combined.
Endometrial hyperplasia: ~5–10%. Thickened lining, sometimes precancerous.
Endometrial cancer: ~9–10%. The reason we work every case up.
Cervical / vulvar lesions: pap-detectable causes.
Medications: anticoagulants, tamoxifen, some SSRIs.

The evaluation you should expect

Pelvic exam and cervical screening.
Transvaginal ultrasound — a stripe ≤4 mm has <1% cancer risk.
In-office endometrial biopsy if stripe >4 mm or bleeding persists.
Hysteroscopy or saline-infusion sonography for polyps.

Treating the cause

Atrophy: low-dose vaginal estrogen (tablet, ring, or cream) — resolves most cases within 6–8 weeks.
Polyps: hysteroscopic removal, day surgery.
HRT-related: regimen adjustment (dose, cyclic vs. continuous, progestogen type).
Hyperplasia: progestin therapy or hysterectomy depending on subtype.
Cancer: gynecologic-oncology referral. Stage I 5-year survival exceeds 95%.

When to seek urgent care

Soaking a pad per hour for >2 hours, severe pelvic pain, dizziness, or fainting. Otherwise, book an appointment within 1–2 weeks.

Sources

ACOG Committee Opinion 734 — Postmenopausal Bleeding
NAMS 2022 Hormone Therapy Position Statement
SGO Endometrial Cancer Practice Statement

Frequently asked questions

What causes vaginal spotting after menopause?

The most common cause is vaginal or endometrial atrophy — thinning tissue from low estrogen that bleeds easily after intercourse, exercise, or a bowel movement. Other causes include polyps, hormone therapy, endometrial hyperplasia, and (in ~9–10% of cases) endometrial cancer.

Is a small amount of spotting after menopause serious?

Any bleeding after 12 consecutive months without a period is defined as postmenopausal bleeding and warrants evaluation, even one pink spot. Most causes are benign, but ruling out cancer early is essential.

Can vaginal dryness cause spotting?

Yes — severe vaginal atrophy is the leading cause. Thin, fragile tissue with fewer blood-vessel supporting layers bleeds with minimal friction. Low-dose vaginal estrogen usually resolves it within 6–8 weeks.

Can spotting be from HRT?

Yes. Sequential HRT is designed to produce a monthly withdrawal bleed. Continuous combined HRT often causes irregular spotting for 3–6 months before settling. New spotting after 6 months of continuous HRT still needs evaluation.

What tests will I need?

Pelvic exam, transvaginal ultrasound to measure endometrial thickness, endometrial biopsy if the stripe is >4 mm or bleeding is persistent, and sometimes hysteroscopy.

How is postmenopausal spotting treated?

Treatment depends on the cause. Atrophy: low-dose vaginal estrogen. Polyps: hysteroscopic removal. HRT-related: regimen adjustment. Hyperplasia: progestin therapy or hysterectomy. Cancer: gynecologic-oncology referral.

Considering a physician-supervised longevity protocol? Kindr Health evaluates peptide therapy as part of personalized perimenopause and menopause care.

Request your Longevity Consult →

Medically reviewed by Kindr Health Clinical Team · Last reviewed 2026-06-19. Compounded medications are prepared by FDA-registered 503A pharmacies and are not FDA-approved drug products.